Zhong Guo Jing Ji Wang·2025-11-19 08:59Core Viewpoint - Huyou Pharmaceutical (688553.SH) has experienced a significant decline in stock price, closing at 20.60 yuan with a drop of 5.24%, indicating a state of breaking down [1]. Group 1: Company Overview - Huyou Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1]. - On the first day of trading, the stock reached a peak price of 42.59 yuan, marking the highest point since its listing [2]. Group 2: Fundraising and Financials - The total amount raised from the IPO was 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [2]. - The funds are intended for the construction of the Huyou EU Standard Injectable Drug Industrialization Base (Phase II), the Huyou Innovative Drug Research Institute, and to supplement working capital [2]. - The total issuance costs amounted to 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities totaling 98.875 million yuan [3].